Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
Laura Pérez‐Alós, José Juan Almagro Armenteros, Johannes Roth Madsen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications
Fen Zhang, Raphaela Iris Lau, Qin Liu, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 5, pp. 323-337
Open Access | Times Cited: 193
A multinational Delphi consensus to end the COVID-19 public health threat
Jeffrey V. Lazarus, Diana Romero, Christopher J. Kopka, et al.
Nature (2022) Vol. 611, Iss. 7935, pp. 332-345
Open Access | Times Cited: 177
Determinants of COVID-19 vaccine fatigue
Tanja Stamm, Julia Partheymüller, Erika Mosor, et al.
Nature Medicine (2023) Vol. 29, Iss. 5, pp. 1164-1171
Open Access | Times Cited: 56
SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
Jernej Pušnik, Werner O. Monzon-Posadas, Jasmin Zorn, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 45
COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis
Shaimaa Abdelaziz Abdelmoneim, Malik Sallam, Dina Mohamed Hafez, et al.
Tropical Medicine and Infectious Disease (2022) Vol. 7, Iss. 10, pp. 298-298
Open Access | Times Cited: 65
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines
Tomabu Adjobimey, Julia Meyer, Leander Sollberg, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 54
The immune response to SARS-CoV-2 in people with HIV
Maxine A. Höft, Wendy A. Burgers, Catherine Riou
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 2, pp. 184-196
Open Access | Times Cited: 38
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Rupsha Fraser, Aurelio Orta‐Resendiz, Alexander Mazein, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 4, pp. 255-267
Open Access | Times Cited: 35
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Laura Pérez‐Alós, Cecilie Bo Hansen, José Juan Almagro Armenteros, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 33
Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England
Vahé Nafilyan, Charlotte Bermingham, Isobel Ward, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 31
Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection
Denis Mongin, Nils Bürgisser, Gustavo Laurie, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin
Jernej Pušnik, Jasmin Zorn, Werner O. Monzon-Posadas, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 5, pp. 685-685
Open Access | Times Cited: 10
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
Chapin S. Korosec, David W. Dick, Iain R. Moyles, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Nucleocapsid Antibodies as an Optimal Serological Marker of SARS‐CoV‐2 Infection: A Longitudinal Study at the Thomayer University Hospital
Markéta Ibrahimová, V Jamriková, Kateřina Pavelková, et al.
Journal of Clinical Laboratory Analysis (2025)
Open Access | Times Cited: 1
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Feyza Gül Özbay Kurt, Alisa Lepper, Catharina Gerhards, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark
Sebastian Rask Hamm, Omid Rezahosseini, Dina Leth Møller, et al.
American Journal of Transplantation (2022) Vol. 22, Iss. 11, pp. 2637-2650
Open Access | Times Cited: 34
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 30
Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study
Natsuko Imai, Thomas Rawson, Edward Knock, et al.
The Lancet Public Health (2023) Vol. 8, Iss. 3, pp. e174-e183
Open Access | Times Cited: 19
Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
Line Dam Heftdal, Laura Pérez‐Alós, Rasmus Bo Hasselbalch, et al.
EBioMedicine (2023) Vol. 93, pp. 104661-104661
Open Access | Times Cited: 19
Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
Isabelle Montgomerie, Thomas W. Bird, Olga R. Palmer, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106256-106256
Open Access | Times Cited: 17
Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study
John S. Kim, Yifei Sun, Pallavi Balte, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Tanmay Ghildiyal, Nishant Rai, Janhvi Mishra Rawat, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-19
Open Access | Times Cited: 7
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2
Alexander P. Underwood, Christina Sølund, Kivin Jacobsen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination
Stefan Gravenstein, Frank DeVone, Oladayo A Oyebanji, et al.
EBioMedicine (2024) Vol. 105, pp. 105180-105180
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top